Free Trial

Gilead Sciences (GILD) 10K Form and Latest SEC Filings 2026

Gilead Sciences logo
$133.73 -0.63 (-0.47%)
As of 04:00 PM Eastern

Latest Gilead Sciences SEC Filings & Recent Activity

Gilead Sciences (NASDAQ:GILD) has submitted 744+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Gilead Sciences's financial statements. The most recent filing was a Form 8-K submitted on May 20, 2026.

Form 4
GILEAD SCIENCES, INC. Reports Ownership Change on May. 18, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Gilead Sciences Files Current Report on May. 20, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Gilead Sciences Files Quarterly Report on May. 7, 2026

The 10-Q contains Gilead Sciences's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Gilead Sciences SEC Filing History

Browse Gilead Sciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/20/2026 3:15 PM
Gilead Sciences (882095) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/18/2026 4:45 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 4:50 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 3:15 PM
Gilead Sciences (882095) Filer
Form 424B5
05/14/2026 4:11 PM
Gilead Sciences (882095) Subject
Form FWP
05/14/2026 7:46 AM
Gilead Sciences (882095) Filer
Form 424B5
05/08/2026 4:00 PM
Gilead Sciences (882095) Filer
Form 13F-HR
Initial Quarterly Form 13F Holdings report filed by institutional managers
05/07/2026 4:12 PM
Gilead Sciences (882095) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/07/2026 4:13 PM
Gilead Sciences (882095) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
05/07/2026 3:03 PM
Gilead Sciences (882095) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/04/2026 3:31 PM
Gilead Sciences (882095) Issuer
Horning Sandra (1638709) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 3:36 PM
BARTON JACQUELINE K (1183680) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 3:19 PM
Gilead Sciences (882095) Issuer
Kramer Kelly A. (1629885) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 3:20 PM
Gilead Sciences (882095) Issuer
MANWANI HARISH (1527726) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 3:05 PM
Gilead Sciences (882095) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2026 5:41 PM
Gilead Sciences (882095) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/29/2026 4:53 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 8:13 AM
Arcellx, Inc. (1786205) Subject
Gilead Sciences (882095) Filed by
Form SCHEDULE 13D/A
04/28/2026 7:53 AM
Arcellx, Inc. (1786205) Subject
Gilead Sciences (882095) Filed by
Form SC TO-T/A
04/28/2026 7:56 AM
Gilead Sciences (882095) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/17/2026 8:00 AM
Arcellx, Inc. (1786205) Subject
Gilead Sciences (882095) Filed by
Form SC TO-T/A
04/16/2026 5:40 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/16/2026 5:41 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 3:12 PM
Gilead Sciences (882095) Subject
Mercier Johanna (1782135) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/15/2026 3:08 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/01/2026 3:34 PM
Arcellx, Inc. (1786205) Subject
Gilead Sciences (882095) Filed by
Form SC TO-T/A
03/30/2026 4:59 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2026 3:03 PM
Gilead Sciences (882095) Subject
O'Day Daniel Patrick (1638643) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/26/2026 5:40 PM
Gilead Sciences (882095) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/17/2026 5:56 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/17/2026 5:14 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 3:45 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 3:24 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 3:46 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/23/2026 1:49 PM
Arcellx, Inc. (1786205) Subject
Gilead Sciences (882095) Filed by
Form SC TO-C
02/23/2026 5:46 AM
Gilead Sciences (882095) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/23/2026 5:48 AM
Arcellx, Inc. (1786205) Subject
Gilead Sciences (882095) Filed by
Form SC TO-C
02/23/2026 5:51 AM
Arcellx, Inc. (1786205) Subject
Gilead Sciences (882095) Filed by
Form SCHEDULE 13D
02/18/2026 4:11 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 4:31 PM
Gilead Sciences (882095) Reporting
Xilio Therapeutics, Inc. (1840233) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/12/2026 6:26 PM
Cain Wettan Keeley M (2110603) Reporting
Gilead Sciences (882095) Issuer
Form 3
Initial statement of beneficial ownership of securities  
The chokepoint supplier behind SpaceX's $1.75 trillion empire (Ad)

When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.tc pixel

See the stock Musk's own words pointed to right here
02/06/2026 3:22 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 5:49 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 5:51 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 5:46 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 12:23 PM
FMR LLC (315066) Filed by
Gilead Sciences (882095) Subject
Form SCHEDULE 13G
01/29/2026 4:23 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2026 6:29 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2026 3:03 PM
Gilead Sciences (882095) Subject
O'Day Daniel Patrick (1638643) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2026 3:32 PM
Gilead Sciences (882095) Subject
Telman Deborah H (1860008) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/21/2026 3:26 PM
Bluestone Jeffrey (1771814) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/20/2026 3:01 PM
Bluestone Jeffrey (1771814) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/16/2026 5:10 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2026 5:18 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2026 3:01 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/15/2026 3:02 PM
Gilead Sciences (882095) Subject
Mercier Johanna (1782135) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/05/2026 4:56 PM
Berger Dietmar (1739515) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 3:23 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 5:31 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 5:12 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 3:04 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/15/2025 3:04 PM
Gilead Sciences (882095) Subject
Mercier Johanna (1782135) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/11/2025 7:38 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 7:40 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 5:25 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 5:11 PM
Bluestone Jeffrey (1771814) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 3:36 PM
Gilead Sciences (882095) Reporting
Xilio Therapeutics, Inc. (1840233) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/28/2025 12:02 PM
Bluestone Jeffrey (1771814) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/28/2025 12:05 PM
Gilead Sciences (882095) Subject
O'Day Daniel Patrick (1638643) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/26/2025 3:16 PM
Gilead Sciences (882095) Subject
Kramer Kelly A. (1629885) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/19/2025 7:30 AM
Gilead Sciences (882095) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/18/2025 6:00 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/18/2025 5:51 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/17/2025 3:05 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/17/2025 3:06 PM
Gilead Sciences (882095) Subject
Mercier Johanna (1782135) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/13/2025 6:36 PM
Gilead Sciences (882095) Issuer
Telman Deborah H (1860008) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2025 4:07 PM
Gilead Sciences (882095) Subject
Wilfong Diane E. (1374988) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/13/2025 3:44 PM
Gilead Sciences (882095) Filer
Form 13F-HR
Initial Quarterly Form 13F Holdings report filed by institutional managers
11/05/2025 4:19 PM
Arcus Biosciences, Inc. (1724521) Subject
Gilead Sciences (882095) Filed by
Form SCHEDULE 13D/A
10/29/2025 3:14 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/28/2025 4:47 PM
Gilead Sciences (882095) Subject
O'Day Daniel Patrick (1638643) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/27/2025 6:43 PM
Gilead Sciences (882095) Issuer
Telman Deborah H (1860008) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2025 8:35 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2025 8:28 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2025 3:03 PM
Gilead Sciences (882095) Subject
Mercier Johanna (1782135) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/15/2025 3:05 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/06/2025 7:17 AM
Gilead Sciences (882095) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/03/2025 3:30 PM
ASSEMBLY BIOSCIENCES, INC. (1426800) Issuer
Gilead Sciences (882095) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/30/2025 3:57 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/29/2025 3:09 PM
Gilead Sciences (882095) Subject
O'Day Daniel Patrick (1638643) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/23/2025 6:53 PM
Burkhart Erin (1927648) Reporting
Gilead Sciences (882095) Issuer
Form 3
Initial statement of beneficial ownership of securities  
Musk's shopping list: batteries ✓ solar ✓ data ✓ power ___ (Ad)

Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant.tc pixel

See the stock Musk's acquisition pattern points to next
09/23/2025 6:55 PM
Burkhart Erin (1927648) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/16/2025 4:12 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/16/2025 4:16 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/15/2025 3:38 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/15/2025 3:04 PM
Gilead Sciences (882095) Subject
Mercier Johanna (1782135) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/11/2025 6:31 PM
Gilead Sciences (882095) Issuer
Telman Deborah H (1860008) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/11/2025 6:34 PM
Gilead Sciences (882095) Issuer
Wilfong Diane E. (1374988) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/11/2025 6:38 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/11/2025 5:31 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Gilead Sciences SEC Filings - Frequently Asked Questions

Gilead Sciences (GILD) has submitted 744+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Gilead Sciences's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Gilead Sciences's financial statements page.

The most recent filing was a Form 8-K submitted on May 20, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:GILD) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners